Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raynier Devillier

Showing results (51-60 of 88) with videos related to

Pageof 9
Sort By:
American Journal of Hematology|October 11, 2013
A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donorRaynier Devillier, Sabine Fürst, Roberto Crocchiolo, et al.
Bone Marrow Transplantation|March 22, 2024
Transplantation for myelofibrosis patients in the ruxolitinib era: a registry study from the Société Francophone de Greffe de Moelle et de Thérapie CellulaireSara Villar, Sylvie Chevret, Xavier Poire, et al.
Blood Advances|September 15, 2021
In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO studyRaynier Devillier, Edouard Forcade, Alice Garnier, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 22, 2020
Nonmyeloablative Conditioning Regimen before T Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Hodgkin and Non-Hodgkin LymphomasCatalina Montes de Oca, Luca Castagna, Chiara De Philippis, et al.
Oncoimmunology|December 7, 2017
NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AMLAnne-Sophie Chretien, Raynier Devillier, Cyril Fauriat, et al.
The Journal of Allergy and Clinical Immunology|August 23, 2025
Beyond conventional adoptive T cell therapyMarina Cavazzana, Juliette Paillet, Abderrahim Fandi, et al.
Bone Marrow Transplantation|March 21, 2019
Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patientsAngela Granata, Sabine Fürst, Stefania Bramanti, et al.
Bone Marrow Transplantation|December 30, 2022
Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignanciesRémy Duléry, Claire Goudet, Daniele Mannina, et al.
Bone Marrow Transplantation|October 10, 2022
Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: A study on behalf of the EBMT cellular therapy & immunobiology working partyNicole Santoro, Jarl E Mooyaart, Raynier Devillier, et al.
Haematologica|November 27, 2014
Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trialDidier Blaise, Raynier Devillier, Anne-Gaëlle Lecoroller-Sorriano, et al.
Pageof 9

Showing results (51-60 of 88) with videos related to

Sort By:
Pageof 9
American Journal of Hematology|October 11, 2013
A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donorRaynier Devillier, Sabine Fürst, Roberto Crocchiolo, et al.
Bone Marrow Transplantation|March 22, 2024
Transplantation for myelofibrosis patients in the ruxolitinib era: a registry study from the Société Francophone de Greffe de Moelle et de Thérapie CellulaireSara Villar, Sylvie Chevret, Xavier Poire, et al.
Blood Advances|September 15, 2021
In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO studyRaynier Devillier, Edouard Forcade, Alice Garnier, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 22, 2020
Nonmyeloablative Conditioning Regimen before T Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Hodgkin and Non-Hodgkin LymphomasCatalina Montes de Oca, Luca Castagna, Chiara De Philippis, et al.
Oncoimmunology|December 7, 2017
NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AMLAnne-Sophie Chretien, Raynier Devillier, Cyril Fauriat, et al.
The Journal of Allergy and Clinical Immunology|August 23, 2025
Beyond conventional adoptive T cell therapyMarina Cavazzana, Juliette Paillet, Abderrahim Fandi, et al.
Bone Marrow Transplantation|March 21, 2019
Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patientsAngela Granata, Sabine Fürst, Stefania Bramanti, et al.
Bone Marrow Transplantation|December 30, 2022
Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignanciesRémy Duléry, Claire Goudet, Daniele Mannina, et al.
Bone Marrow Transplantation|October 10, 2022
Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: A study on behalf of the EBMT cellular therapy & immunobiology working partyNicole Santoro, Jarl E Mooyaart, Raynier Devillier, et al.
Haematologica|November 27, 2014
Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trialDidier Blaise, Raynier Devillier, Anne-Gaëlle Lecoroller-Sorriano, et al.
Pageof 9